.svg)
You are now leaving Astellas.us. The website you are linking to is neither owned nor controlled by Astellas.
Astellas is not responsible for the content or services on this site.
News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
Dec 14, 2018Acquisition adds clinical stage novel immuno-oncology programs to Astellas' oncology pipeline
Nov 28, 2018- FLT3 mutation-positive AML is a life-threatening disease[1] with significant unmet medical needs --
Nov 20, 2018Navigation Acuity Tool to be Developed by Astellas US LLC and AONN+
-
Nov 19, 2018- Abstracts include updated results from Phase 1 study of gilteritinib in patients with newly diagnosed AML -
Oct 4, 2018Three innovators working to change cancer care awarded a combined $100,000 in grants following live pitch to a panel of judges that included celebrity entrepreneur Bill Rancic